Considering his obesity, poor glycemic control, and the added benefit of weight reduction, a GLP-1 receptor agonist (semaglutide) was initiated at a dose of 0.25 mg once weekly, with plans for gradual titration based on tolerance and glycemic response. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.